Longevity Supplement Improves Blood Vessel Function in Surrey Trial

10 November 2026, Guildford, UK: A multi-ingredient nutritional supplement marketed for healthy ageing improved several measures of blood vessel health over six months in a small randomized trial at the University of Surrey. The researchers reported the results on 4 November 2026 in the European Heart Journal Open. The supplement’s maker supported the study, and the researchers stress that it measured markers of vascular health, not heart attacks or strokes.

The trial enrolled 61 apparently healthy adults aged over 40 in the UK. They were randomly assigned to take either the supplement or a look-alike, flavour-matched inactive powder once a day. Neither participants nor researchers knew who received which (a double-blind design). Of those enrolled, 43 completed both the starting and six-month assessments, 24 in the supplement group and 19 in the control group. Recruitment ran from July 2023 to January 2025.

The main outcome was flow-mediated dilation (FMD), a standard ultrasound test of how well the artery in the upper arm widens when blood flow increases. Healthy arteries widen more, and lower FMD is linked to higher cardiovascular risk. After six months, FMD in the supplement group was 2.9 percentage points higher than in the control group. A difference of 3.9 percentage points was also seen one hour after the very first supervised dose.

Other markers moved in the same direction. Pulse wave velocity, a measure of arterial stiffness where lower values are better, fell by 1.18 metres per second relative to control. Peripheral systolic blood pressure, the upper number in a standard reading, was 6.1 mmHg lower. Using standard European risk scores, the researchers estimated a 0.45 percentage point reduction in 10-year cardiovascular risk. Diastolic blood pressure, central (aortic) blood pressure, cholesterol and triglyceride levels did not change significantly.

What was in the powder

The product tested was NOVOS Core, supplied by NOVOS Labs of New York. It is a powder combining more than a dozen compounds that its developers say target biological processes associated with ageing. According to the published ingredient table, these include:

• the amino acid glycine
• calcium alpha-ketoglutarate, a compound involved in cellular energy metabolism
• magnesium malate
• vitamin C
• glucosamine
• hyaluronic acid
• L-theanine, an amino acid found in tea
• extracts of Rhodiola rosea root and ginger root
• the plant compounds fisetin and pterostilbene
• a small amount of lithium, in the form of lithium aspartate

The powder was dissolved in water or juice.

Because the formula combines many ingredients, the trial cannot show which component, or which combination, was responsible for the effects. Several of the ingredients are derived from plants or produced by fermentation. The trial adds to a fast-growing commercial category of multi-ingredient longevity products whose individual components have mostly been studied separately, often in animals.

Funding and limitations

The University of Surrey described the trial as investigator-initiated. NOVOS Labs provided the supplement and the matching placebo and made an unrestricted contribution toward research costs. According to the university, the company had no role in the study design, data collection, primary interpretation or the decision to publish, and Surrey researchers kept control of the data. The paper’s conflict-of-interest statement lists one co-author as a NOVOS Labs employee. It also notes that the corresponding author, Professor Christian Heiss, Professor of Cardiovascular Medicine at the University of Surrey, has received research funding from NOVOS Labs among other funders, which the statement describes as unrelated to the present work.

The researchers acknowledge that the measures used are not clinical outcomes and that the study was not designed to test whether the supplement prevents cardiovascular events. Heiss said larger studies are now needed. Other features also call for caution:

• The trial was small and run at a single centre.
• The main results are based on the 43 participants who completed both visits, so nearly 30 percent of those randomized were not included in the primary analysis.
• The six-month improvement in FMD was considerably larger than the roughly one percentage point effect the researchers assumed when planning the sample size. Independent replication would need to confirm it.

The trial was registered in advance on the US government’s clinical trials database under the identifier NCT06145087. Participants were recruited through public advertising, and the University of Surrey’s ethics committee approved the study. The authors include researchers from the University of Surrey and from East Surrey Hospital, part of the Surrey and Sussex Healthcare NHS Trust.

Also Read: Syngenta Expands Zivalgo, Incipio Insecticide Use In Florida

Global Agriculture is an independent international media platform covering agri-business, policy, technology, and sustainability. For editorial collaborations, thought leadership, and strategic communications, write to pr@global-agriculture.com